Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On August 14, 2024, Kamada Ltd. (KMDA) announced financial results for the second quarter of 2024.</li><li>Revenues for the second quarter of 2024 were $42.5 million, which was a 13% increase compared to the second quarter of 2023.</li><li>Adjusted EBITDA was $9.1 million, which was a 51% increase from the second quarter of 2023.</li></ul>

On August 14, 2024, Kamada Ltd. (KMDA) announced financial results for the second quarter of 2024.Revenues for the second quarter of 2024 were $42.5 million, which was a 13% increase compared to the second quarter of 2023.Adjusted EBITDA was $9.1 million, which was a 51% increase from the second quarter of 2023.

KMDA: Revenues Up 13% YoY  Adjusted EBITDA Up 51% YoY 

<ul><li>On May 8, 2024, Kamada Ltd. (KMDA) announced financial results for the first quarter of 2024.</li><li>Revenues for the first quarter of 2024 were $37.7 million, which was a 23% increase compared to the first quarter of 2023.</li><li>Adjusted EBITDA was $7.5 million, which was a 96% increase from the $3.8 million in the first quarter of 2023.</li></ul>

On May 8, 2024, Kamada Ltd. (KMDA) announced financial results for the first quarter of 2024.Revenues for the first quarter of 2024 were $37.7 million, which was a 23% increase compared to the first quarter of 2023.Adjusted EBITDA was $7.5 million, which was a 96% increase from the $3.8 million in the first quarter of 2023.

KMDA: Full Year Guidance Raised  Year-Over-Year Top-Line Growth of 23% 

Director, RaaS Advisory, Research as a Service (RaaS)

Research as a Service (RaaS)

Director, RaaS Advisory

Insightful Financial Models and Research Analysis

Connect to the right investors through smart and insightful financial models and research analysis.

Thematic (Sector/Industry)

<ul><li>We have applied some screens to 15 ASX-listed retail stocks to determine which potentially present the best returns.</li><li>As a retail analyst in a former life, I have learnt two things about consumers: buyer fatigue and pent-up demand.</li><li>We saw online buyer fatigue post-Covid and we are arguably in a period that will lead to pent-up demand following the tightening of consumer belts in the current cost-of-living/interest rate environment.</li></ul>

We have applied some screens to 15 ASX-listed retail stocks to determine which potentially present the best returns.As a retail analyst in a former life, I have learnt two things about consumers: buyer fatigue and pent-up demand.We saw online buyer fatigue post-Covid and we are arguably in a period that will lead to pent-up demand following the tightening of consumer belts in the current cost-of-living/interest rate environment.

Mid-Cap Discretionary Retail Analysis -Screening for Best Recovery Plays

Israel

Kamada Ltd is a bio-pharmaceutical company. The Company develops, produces, and markets specialty plasma therapeutics, specific and general immune globulins, and other prescribed medicines using chromatographic purification technology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kamada (KMDA US)

KMDA: Revenues Up 13% YoY Adjusted EBITDA Up 51% YoY

On August 14, 2024, Kamada Ltd. (KMDA) announced financial results for the second quarter of 2024. Revenues for the second quarter of 2024 were...

Zacks Small Cap Research

KMDA: Full Year Guidance Raised Year-Over-Year Top-Line Growth of 23%

On May 8, 2024, Kamada Ltd. (KMDA) announced financial results for the first quarter of 2024. Revenues for the first quarter of 2024 were $37.7...

Zacks Small Cap Research

Mid-Cap Discretionary Retail Analysis -Screening for Best Recovery Plays

Investors may place more emphasis on one criteria over another but our analysis reveals (ASX:DSK), (ASX:UNI) and (ASX:NCK) tick the most boxes.

Research as a Service (RaaS)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)